CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 70 enrolled
Drug / intervention
Botulinum Toxin Type A +1 moredrug
Likely dose
Botulinum Toxin Type A 100 unitsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

In the news

1 article

Matched to this trial by ClinicalIndexfrom reputable biotech & medical press.

Search/NCT03102762
NCT03102762Phase 3Completed
CompareCT.gov

Intracavernosal Injection of Botulinum Toxin Type A in the Treatment of Erectile Dysfunction (Phase 2 Study)

Cairo University·interventional·Posted Apr 6, 2017·Updated Jan 7, 2020

In Brief

A Phase 3 clinical trial evaluating Botulinum Toxin Type A and Normal saline for Sexual Dysfunction and Erectile Dysfunction. Completed, enrolled 70 participants across 1 site.

Detailed Summary

To evaluate the safety and efficacy of intra-cavernosal Botulinum toxin injection as an alternative line of treatment in patients with erectile dysfunction - not responding to oral PDE5i - through cavernosal smooth muscle relaxation.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSexual Dysfunction, Erectile Dysfunction
CountriesEgypt
Collaborators--

Timeline

Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedApr 6, 2017
Enrollment StartJan 3, 2017
Primary CompletionJan 10, 2019
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 9.2 years ago

Interventions

Botulinum Toxin Type Adrug

Drug: Botulinum Toxin Type A The treatment group will be injected with 100 units BTX-A one day following penile colour doppler assessment.

Normal salinedrug

The treatment group will be injected with 1 ml normal saline one day following penile colour doppler assessment.